Your gym friend is icing a cranky shoulder and swears TB-500 is “already human-tested.” He shows you a forum post that says thymosin beta-4 went through placebo-controlled safety trials and “nothing bad happened,” so a research vial must be fine for a home recovery plan. He wants you to tell him he is right.
Those human trials are real. They tested full-length thymosin beta-4 made by drug developers, in healthy volunteers, for tolerability. They did not test a catalog product called TB-500, and they did not test shoulders.
What the two phase 1 studies actually measured
Ruff and colleagues reported a randomized, placebo-controlled phase 1 study in the Annals of the New York Academy of Sciences in 2010. Forty healthy adults in four groups received synthetic thymosin beta-4 or placebo by intravenous infusion, first as a single infusion and then as repeated daily infusions for about two weeks, at increasing amounts across groups. The team tracked side effects and how the drug moved through the blood. Adverse events were infrequent and mild or moderate, with no serious events and no dose-limiting toxicity. The stated goal was a future heart-attack treatment.
Wang and colleagues reported a first-in-human, randomized, double-blind phase 1 study of a recombinant human thymosin beta-4, coded NL005, in the Journal of Cellular and Molecular Medicine in 2021. Fifty-four healthy Chinese volunteers took part in the single-infusion part and thirty in a ten-day repeated part, each followed for twenty-eight days. Again, side effects were mild to moderate, with no serious events. Several authors worked for the company developing the drug, and the study was designed to support later trials in acute myocardial infarction.
Neither trial measured tendon, muscle, or joint healing. Neither enrolled injured people. Both used hospital infusions with medical staff watching every visit.
Why a safety result does not carry over to a catalog vial
A phase 1 safety finding belongs to a specific molecule, maker, purity standard, route, and supervised setting. TB-500 is a catalog name. Depending on the seller, it can describe a short synthetic fragment or another version that was never put through these trials. Everyday Brief has covered how TB-500 ads borrow animal work on thymosin beta-4, and how separate eye-drop trials of a thymosin beta-4 product for dry eye do not transfer to TB-500 either. Healthy-volunteer tolerability is a third, narrower file.
Small phase 1 groups are also built to catch common, short-term problems. They cannot rule out rare harms, long-term effects, or problems from contamination in products made outside drug manufacturing rules. Research-catalog peptides are laboratory materials, not approved medicines.
For competitive athletes there is one more layer: anti-doping rules list thymosin beta-4 and related peptides as prohibited, regardless of what a forum says about safety.
What to do with a sore shoulder instead
Ask the forum poster which paper they mean. If it is one of these two trials, you know the limits: healthy volunteers, drug-company molecules, hospital infusions, and no healing outcome. Then take the shoulder to a clinician or physical therapist who can examine it, rule out a tear, and build a rehab plan with measurable goals.
“Passed a safety study” sounds like a finish line. For TB-500, it describes a different molecule crossing a much smaller starting line.
Not medical advice.
Sources
- Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 2010 (PubMed)
- Wang X et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med, 2021 (PubMed)
- Full text: Wang et al. 2021 recombinant thymosin beta4 phase I study (PubMed Central)
- MedlinePlus: Shoulder injuries and disorders
Related reading
- How TB-500 ads borrow thymosin beta-4 animal studies
- Thymosin beta-4 eye drops: what the dry-eye trials showed
- BPC-157, TB-500 and anti-doping rules for athletes
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-14 PT. Not medical advice.